Aspirin may reduce risk for hepatocellular carcinoma, liver-related mortality in chronic viral hepatitis

Low-dose aspirin use appeared associated with significantly lower risk for hepatocellular carcinoma and lower liver-related mortality among patients with chronic viral hepatitis, according to results of a retrospective study published in The New England Journal of Medicine.Moreover, low-dose aspirin did not significantly increase risk for gastrointestinal bleeding in this patient population.“There is growing evidence that…

Healthy lifestyle linked with reduced mortality in IBD

Patients who adhere to health lifestyle choices, including those related to diet, exercise and smoking habits, had reduced mortality, according to study results.Ashwin N. Ananthakrishnan, MD, MPH, of the division of gastroenterology at Massachusetts General Hospital, and colleagues wrote that these lifestyle factors have been associated with reduced mortality in the general population, but some…

Q&A: What GIs need to know about COVID-19

As the concern about COVID-19 continues to spread, the entire medical community is on alert. Associations are cancelling or altering plans for scientific conferences, and institutions are implementing travel bans for faculty.In gastroenterology, two recent studies have shown that patients with the disease may exhibit GI symptoms, and it may have the potential to spread…

FDA approves Opdivo-Yervoy combination for previously treated hepatocellular carcinoma

The FDA granted accelerated approval to nivolumab plus ipilimumab for treatment of patients with hepatocellular carcinoma who previously received sorafenib.The combination is the first dual immunotherapy approved in this setting, according to the agents’ manufacturer.Nivolumab (Opdivo, Bristol-Myers Squibb) is an anti-PD-1 antibody. Ipilimumab (Yervoy, Bristol-Myers Squibb) is an anti-CTLA-4 antibody.The FDA based the approval on…